Abstract:Thymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation. Its synthetic form, thymalfasin, has been approved by various regulatory agencies in the treatment of hepatitis B viral infection and as an enhancer of vaccine response in immune-compromised populations. In China, it has also widely utilized in patients with cancer and severe infections, as well as the emergency use during (Severe Acute Respiratory Syndrome)SARS and COVID-19 pandemic as an immune-regulator. Recent studies showed that Tα1 could significantly improve overall survival (OS) in patients with surgically resectable non-small cell lung cancer (NSCLC) and liver cancers in the adjuvant setting. For patients with locally advanced, unresectable NSCLC, Tα1 could significantly reduce chemoradiation-induced lymphopenia, pneumonia, and trending improvement of OS. Preclinical evidence are emerging to demonstrate that Tα1 may augment efficacy of cancer chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis and enhancing anti-tumor immunity by turning "cold-tumors" to "hot-tumors"; a protective role in reducing colitis caused by immune check-point inhibitors (ICIs). Potential enhancement of ICIs' clinical efficacies has also been indicated. ICIs have transformed ways treating patients with cancer but limitations such as relatively low response rates and certain safety issues remains. Given the roles of Tα1 in regulating cellular immunities and exceptional safety profiles demonstrated in decades clinical uses, we believe that it is plausible to explore implications of Tα1 the immune-oncology setting by combining with ICI-based therapeutic strategies. Background Activities of Tα1. Tα1 is a biological response modifier which activates various cells in the immune system [1-3]. Tα1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective. These disorders include acute and chronic infections, cancers, and vaccine non-responsiveness. In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. Tα1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.

The In Vitro Immunomodulatory and Anti-Tumor Activity of Thymosin alpha 1-Thymopentin Fusion Peptide

The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.

Thymosin Α-1 in Cancer Therapy: Immunoregulation and Potential Applications

Expression of Thymosin Α1-Thymopentin Fusion Peptide in Pichia Pastoris and Its Characterization

Increased antitumor activity of tumor-specific peptide modified thymopentin.

Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer

Thymopentin (TP5), an Immunomodulatory Peptide, Suppresses Proliferation and Induces Differentiation in HL-60 Cells.

Effect of Thymosin Alpha 1 on Cellular Immune Function in Elderly Patients with Malignant Tumor

Intein-mediated Expression, Purification, and Characterization of Thymosin Α1–thymopentin Fusion Peptide in Escherichia Coli

Expression, Purification and Characterization of A Novel Soluble Human Thymosin Alpha1 Concatemer Exhibited A Stronger Stimulation on Mice Lymphocytes Proliferation and Higher Anti-tumor Activity

A Modified Thymosin Alpha 1 Inhibits the Growth of Breast Cancer Both in Vitro and in Vivo: Suppressment of Cell Proliferation, Inducible Cell Apoptosis and Enhancement of Targeted Anticancer Effects

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Effects of Thymic Polypeptides on the Thymopoiesis of Mouse Embryonic Stem Cells

A Reappraisal of Thymosin Alpha1 in Cancer Therapy

Immunomodulatory and Antitumor Activity of Triterpenoid Fractions from the Rhizomes of Astilbe Chinensis.

Immunomodulatory Activity of 3 Beta,6 Beta-Dihydroxyolean-12-En-27-Oic Acid in Tumor-Bearing Mice

Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era

Thymic Immunosuppressive Pentapeptide (TIPP) Shown Anticancer Activity in Breast Cancer and Chronic Myeloid Leukemia Both in Vitro and in Vivo.

Immunomodulatory Function of Orally Administered Thymosin Α1

Proliferative and anti-proliferative effects of thymosin alpha1 on cells are associated with manipulation of cellular ROS levels.

[Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura].